ArticleJACC. Advances2026
Percutaneous Edge-to-Edge Repair of Atrioventricular Valves in Congenital Heart Disease: A Multicenter Clinical Experience.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcatheter Edge-to-Edge Repair in Adult Congenital Heart Disease: Anatomic Challenges, Device Adaptations, and Emerging Evidence.Methodist DeBakey cardiovascular journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter edge-to-edge repair (TEER) has become an established treatment for symptomatic atrioventricular valve regurgitation (AVVR). In congenital heart disease (CHD), AVVR is a major determinant of clinical outcomes. For these patients, surgery often poses high risk, underscoring the importance of percutaneous therapy. However, data supporting TEER in patients with CHD remain limited.
objectivesThe objectives of the study were to examine the outcomes of TEER in CHD patients across several centers and to discuss the procedural considerations.
methodsWe conducted a retrospective review of atrioventricular TEER procedures performed on CHD patients across 5 medical centers. We analyzed patient demographics, procedural details, immediate (30 days), and intermediate (6-month) outcomes.
resultsA total of 20 patients with various CHD diagnoses underwent TEER, of which 18 reached the 6-month follow-up. The median age was 49.3 (Q1-Q3: 37.0-59.8) years and 40.0% were females. All cases were performed on the systemic circulation, 60.0% were tricuspid valves. All patients presented with symptomatic 3+ or 4+ degree AVVR at baseline, which was reduced to mild-to-moderate (1+ to 2+) in 19 patients (95.0%) at 30 days (P < 0.001). One death (5.0%) occurred in the first 30 days due to intractable heart failure; rates of NYHA functional class III-IV were reduced from 18 (90.0%) of the patients at baseline to 10.5% at 30 days.
conclusionsTEER for carefully selected patients with CHD and severe AVVR was safe and effective with notable improvements in regurgitation and clinical symptoms. Our findings highlight important considerations for planning and implementation of TEER in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.